Zealand Pharma down 9%; analyst flags 18% weight loss drug dropout

Zealand Pharma A/S

01/10/2026 09:31

** Shares in Zealand Pharma ZELA.CO fall around 9%; analyst flags that nearly a fifth of patients dropped out of a study for its partner's Boehringer Ingelheim weight-loss drug survodutide
** "What investors are probably also emphasizing is that 18% [of participants] did not end up completing the project due to side effects," Nordnet analyst Per Hansen says
** Hansen adds investors had reservations about side effects with earlier data publication as well
** Zealand dropped 25% in June after data from the trial showed quarter of patients quitting
** Boehringer Ingelheim previously believed it could solve the side effect profile by changes in titration, Hansen says
** Stock is at the bottom of STOXX 600 .STOXX index; if losses hold it will see its worst day since early June

(Reporting by Vera Dvorakova)
((vera.dvorakova@thomsonreuters.com))